Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Detailed results presented at the American Diabetes Association's® 83rd Scientific Sessions  Lilly has completed tirzepatide's submission for chronic weight management to the FDA INDIANAPOLIS , June 24, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in participants with obesity or overweighti and type 2 diabetes, showed that tirzepatide led to superior weight reduction versus placebo for both doses. The data were presented during a symposium at the American Diabetes Association's® (ADA) 83rd Scientific Sessions and were simultaneously published in The Lancet.

Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes

In additional phase 2 data, published in The Lancet, orforglipron achieved mean reduction in A1C up to 2.1% at 26 weeks in adults with type 2 diabetes Lilly is investigating orforglipron, its first nonpeptide oral GLP-1 receptor agonist, for chronic weight management in the ATTAIN phase 3 clinical program and for type 2 diabetes in the ACHIEVE phase 3 clinical program INDIANAPOLIS , June 23, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweighti. The results were shared during an oral presentation at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in the New England Journal of Medicine.

Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight

Results from a mid-stage trial found that the highest dose of Eli Lilly's experimental pill orforglipron helped people who were obese or overweight lose 14.7% of their body weight after 36 weeks, the company said on Friday.

Experimental Lilly pill leads to 14.7% weight loss in mid-stage trial

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

Novo Nordisk

At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.

More News Is Coming on Lilly, Novo Nordisk's New Weight-Loss Drugs

The U.S. Food and Drug Administration has approved the use of Jardiance 10 mg and 25 mg tables to lower blood sugar along with diet and exercise in children aged 10 years and older with type 2 diabetes, according to drug partners Eli Lilly & Co. LLY, +0.18% and privately held Boehringer Ingelheim. Jardiance, or empagliflozin, is not recommended for use in patients with type 1 diabetes, or to improve glycemic control in patients with type 2 diabetes with an eGFR less than 30 mL/min/1.73 m(2), a reading of kidney function.

FDA approves Eli Lilly and Boehringer Ingelheim's Jardiance for children 10 and older with type 2 diabetes

DiCE Molecules Holding LLC

iShares U.S. Healthcare ETF

Harbor Health Care ETF

Horizon Kinetics Medical ETF

VanEck Vectors Pharmaceutical ETF

Health Care Select Sector SPDR Fund

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

-  Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population -  More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS , June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older

Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a note on Wednesday.  UBS, which has a ‘Buy' rating and a 12-month price target of $498 for Eli Lilly, noted that the acquisition provides two oral IL-17 inhibitors DC-806 and DC-853, as well as additional pipeline opportunities to the company's profile.

Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker

Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.

Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

On Tuesday, the nearly 150-year pharmaceutical giant announced an agreement to acquire San Francisco-based immunology specialist DICE Therapeutics. Under the terms of the deal, Lilly will pay $48.00 per share in cash for all outstanding DICE shares, a 42% premium to the small cap's Friday close.

Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover

The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.

US FDA approves Eli Lilly-Boehringer's diabetes drugs for children

Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.

Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know

Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and orforglipron showcase promise of Lilly's pipeline and commitment to transform diabetes and obesity care INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and obesity portfolio and pipeline at the American Diabetes Association's® (ADA) 83rd Scientific Sessions in San Diego from June 23 - 26. Lilly will also share data on three investigational medicines for the treatment of obesity or overweight during two ADA-sponsored symposiums and one oral presentation.

Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions

Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice Therapeutics Inc. ( DICE , Financial) in a deal valued at $2.4 billion.

Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement

Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.

Eli Lilly Buys DICE Therapeutics for $2.4 Billion

Dice Therapeutics Inc (NASDAQ: DICE) opened more than 35% up this morning after Eli Lilly & Co (NYSE: LLY) said it will buy the immunology company for $2.4 billion.

Eli Lilly is buying Dice Therapeutics for $2.4 billion

Dice stock skyrocketed Monday after Eli Lilly pledged to buy the immunology-focused biotech company for $2.4 billion.

Dice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly Buyout

Eli Lilly and Co (NYSE:LLY) said it has signed a definitive agreement to acquire DICE Therapeutics for $2.4 billion, sending shares of the biopharmaceutical company higher in pre-market trade. Under the deal, which has been approved by the boards of both companies, Lilly said it will commence a tender offer to acquire all outstanding shares of DICE for $48 per share in cash, a 42% premium to its previous closing price.

Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover

Estee Lauder

Although these companies are from different sectors, we compare them because they have a similar operating income of $8-10 billion.

Cross-Sector Comparison: Is Estee Lauder A Better Pick Over LLY Stock?

Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.

Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push

Nationwide effort to inform people living with diabetes about how to access affordable insulin and give back to the diabetes community INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association® (ADA) and Adam Duvall, American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all people living with diabetes. Lilly's Tap the Cap campaign underscores how easy it is for people with diabetes to tap Lilly's monthly out-of-pocket insulin cap and access $35 insulin*.

Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"

Lilly said its acquisition of Dice for $48 a share would allow it to leverage the group's developing treatments for chronic diseases in immunology.

Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push

Dice Therapeutics Inc. DICE stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. LLY for $48 a share in a deal that values the immunology company at about $2.4 billion. The price values Dice at a 40% premium over the 30-day, volume-weighted average trading price of its stock as of June 16.

News for Eli Lilly Stock (LLY)